• C4 Therapeutics outlined plans to advance cemsidomide, an oral IKZF1/3 degrader, positioning it as a potential foundational therapy in multiple myeloma across multiple lines of treatment.
• Cash runway expected to extend to end of 2028, supporting portfolio execution through planned clinical and regulatory milestones.
• Phase 2 MOMENTUM trial in 4L+ multiple myeloma targets completion of enrollment in Q1 2027, initial overall response rate data in 2H 2027, potential NDA submission in 2028.
• Phase 1b combination trial of cemsidomide with Pfizer’s elranatamab in 2L+ multiple myeloma started in Q1 2026, with data from all cohorts expected in mid-2027.
• Strategy expansion highlighted targeted protein degradation discovery in inflammation, neuroinflammation, neurodegeneration, with goal of delivering 3 potential INDs in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.